Evidence map›Paper›PMID 39174659›Full record

ReviewNature protocols2024

Fabrication of cyborg bacterial cells as living cell-material hybrids using intracellular hydrogelation.

Ofelya Baghdasaryan, Luis E Contreras-Llano, Shahid Khan, Aijun Wang, Che-Ming Jack Hu, Cheemeng Tan

Abstract readReview
In one paragraph

Review in Nature protocols, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed.

  1. Article
  2. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors.

Ofelya Baghdasaryan *Biomedical Engineering, University of California Davis, Davis, CA, USA.
Luis E Contreras-Llano *Biomedical Engineering, University of California Davis, Davis, CA, USA.ORCID 0000-0002-9686-7375
Shahid Khan *Biomedical Engineering, University of California Davis, Davis, CA, USA.
Aijun WangBiomedical Engineering, University of California Davis, Davis, CA, USA.
Che-Ming Jack HuInstitute of Biomedical Sciences, Academia Sinica, Taipei City, Taiwan. chu@ibms.sinica.edu.tw.ORCID 0000-0002-0988-7029
Cheemeng TanBiomedical Engineering, University of California Davis, Davis, CA, USA. cmtan@ucdavis.edu.ORCID 0000-0003-1049-1192

Funding

Staff InvestigatorsP30CA093373 · NCI · UNIVERSITY OF CALIFORNIA DAVIS · PI KC KENT LLOYD · 2002 to 2026
$84.9M
Engineering and dissecting the synthetic non-dividing-but-active state of hybrid cell-materialsR35GM142788 · NIGMS · UNIVERSITY OF CALIFORNIA AT DAVIS · PI Cheemeng Tan · 2021 to 2026
$2.7M
Engineering non-proliferating-but-active (NPBA) probiotic for breast-cancer gene therapyR21CA267427 · NCI · UNIVERSITY OF CALIFORNIA AT DAVIS · PI HOVEY, RUSSELL C, TAN, CHEEMENG · 2022 to 2023
$374k
NCI NIH HHS P30 CA093373NCI NIH HHS R21 CA267427NIGMS NIH HHS R35 GM142788
6 · The paper itself

Abstract

The production of living therapeutics, cell-based delivery of drugs and gene-editing tools and the manufacturing of bio-commodities all share a common concept: they use either a synthetic or a living cell chassis to achieve their primary engineering or therapeutic goal. Live-cell chassis face limitations inherent to their auto-replicative nature and the complexity of the cellular context. This limitation highlights the need for a new chassis combining the engineering simplicity of synthetic materials and the functionalities of natural cells. Here, we describe a protocol to assemble a synthetic polymeric network inside bacterial cells, rendering them incapable of cell division and allowing them to resist environmental stressors such as high pH, hydrogen peroxide and cell-wall-targeting antibiotics that would otherwise kill unmodified bacteria. This cellular bioengineering protocol details how bacteria can be transformed into single-lifespan devices that are resistant to environmental stressors and possess programable functionality. We designate the modified bacteria as cyborg bacterial cells. This protocol expands the synthetic biology toolset, conferring precise control over living cells and creating a versatile cell chassis for biotechnology, biomedical engineering and living therapeutics. The protocol, including the preparation of gelation reagents and chassis strain, can be completed in 4 d. The implementation of the protocol requires expertise in microbiology techniques, hydrogel chemistry, fluorescence microscopy and flow cytometry. Further functionalization of the cyborg bacterial cells and adaptation of the protocol requires skills ranging from synthetic genetic circuit engineering to hydrogel polymerization chemistries.

Indexed as

HydrogelsSynthetic BiologyBacteriaEscherichia coliHydrogels

Identifiers

PMID39174659
PMCPMC11776454

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.